• Forsythoside E for PKM2 Macrophage Workflows

  2026-09-16

  Forsythoside E converts a PKM2-centered mechanism into a practical workflow for measuring macrophage metabolism, STAT3 signaling, and M2 polarization. Its defined binding, concentration, solubility, and dosing data support mechanism-led studies of sepsis-induced liver injury while helping researchers distinguish target engagement from nonspecific anti-inflammatory effects.

• Repaglinide: Mechanism, Evidence, and AML Context

  2026-09-16

  Repaglinide is a short-acting oral insulin secretagogue that lowers blood glucose by stimulating pancreatic beta-cell insulin release. The cited AML study describes an ATG4B–PRMT1–MRE11 DNA-repair mechanism, but it does not establish repaglinide as an ATG4B inhibitor or leukemia treatment.

• Nanoparticle Uptake by Human Corneal Epithelial Cells

  2026-09-15

  Azadi and David systematically examined how PLGA nanoparticle size and surface chemistry influence uptake by human corneal epithelial cells. Their inhibitor studies identify energy-dependent endocytosis, particularly macropinocytosis and caveolae-mediated entry, as key mechanisms that can guide more rational ocular drug-delivery design.

• Filipin III for Macrophage Cholesterol Mapping

  2026-09-15

  Filipin III converts membrane cholesterol chemistry into spatial and ultrastructural readouts for macrophage and vesicle experiments. This guide connects cholesterol imaging with the 25-hydroxycholesterol–CH25H pathway described in a recent Immunity study while emphasizing controls, workflow design, and interpretation limits.

• Taihangia rupestris: UPLC-MS/MS and Bioactivity

  2026-09-14

  A 2026 RSC Advances study combined UPLC-MS/MS, multivariate analysis, complementary antioxidant assays, α-glucosidase inhibition, affinity screening, and molecular docking to compare wild and cultivated Taihangia rupestris leaves. Foothill cultivation produced the strongest flavonoid- and phenolic-associated profile and activity, supporting cultivation as a conservation-compatible source for natural product antioxidant evaluation and antidiabetic lead discovery.

• Chemistry of Silybin: Structure, Separation, and Derivatives

  2026-09-14

  The reference review establishes a chemical framework for silybin by integrating its historical isolation, stereochemical assignment, diastereomer separation, synthesis, and derivative chemistry. Its central practical contribution is showing why defined silybin A and silybin B standards are essential for interpreting studies that otherwise use the chemically heterogeneous mixture Silymarin.

• Antimycin A4: ATP-Citrate Lyase Workflows

  2026-09-13

  Antimycin A4 combines ATP-citrate lyase inhibition with mitochondrial respiratory-chain blockade, making it useful for separating lipid-biosynthesis effects from cellular energy failure. This guide provides practical biochemical, cell-based, and troubleshooting workflows while emphasizing controls needed to interpret its dual activity.

• GOB-38 in Elizabethkingia: Function and Resistance

  2026-09-12

  The reference study characterizes GOB-38, a B3-Q metallo-β-lactamase from Elizabethkingia anophelis, and shows that its hydrolytic profile spans penicillins, cephalosporins, and carbapenems. By combining recombinant expression, substrate profiling, genomic analysis, cloning, and co-culture experiments, the authors connect enzyme-level activity with broader concerns about carbapenem resistance and interspecies dissemination.

• Valemetostat (DS-3201): EZH1/2 Inhibitor Guide

  2026-09-11

  Valemetostat, also known as DS-3201, is a selective dual EZH1/2 inhibitor designed to suppress PRC2-associated EZH2 methyltransferase activity. The product dossier reports nanomolar EZH2 potency, research relevance in lymphoma models, and formulation constraints that require careful solvent and storage control.

• Nystatin (Fungicidin): Reliable Cell Assays

  2026-09-11

  Learn how Nystatin (Fungicidin), SKU B1993, can support reproducible antifungal controls and contamination-aware cell viability workflows. This scenario-based guide covers mechanism, assay compatibility, stock preparation, species-specific interpretation, and practical vendor selection.

• Cisapride (R 51619) in Cardiac Safety Assays

  2026-09-10

  Cisapride (R 51619) connects 5-HT4 receptor signaling pathway studies with hERG channel inhibition and high-content cardiotoxicity workflows. This guide shows how to use the compound in iPSC-cardiomyocyte assays, orthogonal electrophysiology, and troubleshooting-focused screening designs.

• NHS-Biotin as a Readout for Protein Assemblies

  2026-09-10

  NHS-Biotin is more than a general protein-labeling reagent: it can provide a controlled analytical readout for engineered assemblies. This guide explains how amine-reactive biotinylation complements peptidisc-assisted nanobody multimerization without confusing labeling with the mechanism of assembly.

• PDAC Organoid–Fibroblast Models of Chemoresistance

  2026-09-09

  Schuth et al. developed patient-matched three-dimensional co-cultures that combine pancreatic ductal adenocarcinoma organoids with cancer-associated fibroblasts to model stromal effects on drug response. The system linked fibroblast-associated protection from chemotherapy with inflammatory CAF states, epithelial-to-mesenchymal transition programs, and candidate receptor–ligand interactions, supporting more physiologically relevant personalized drug testing.

• HyperScript RT SuperMix: SQOR qPCR Strategy

  2026-09-09

  A mechanistic and translational framework for validating SQOR, hypoxia, and ferroptosis biology in pancreatic cancer when RNA is scarce, structured, or difficult to represent reproducibly by qPCR.

• Dabigatran Etexilate: Oral Direct Thrombin Inhibition

  2026-09-09

  This clinical review established dabigatran etexilate as a clinically important oral direct thrombin inhibitor with rapid, predictable anticoagulant activity and no routine vitamin K antagonist-style monitoring requirement. Its prodrug design, CYP-independent disposition, renal dosing considerations, and evidence across venous thromboembolism and nonvalvular atrial fibrillation provide a framework for interpreting both its advantages and its safety limitations.

8452 records 1/564 page Next 12345 下5页 Last page